Nutraceuticals in the management of alzheimer’s disease
Meraj Khan*, Seerat Anwar
ONLINE ISSN : 2456-8244ABSTRACT
The aim of this review is attempts to enlist and display the role of some nutraceuticals being used
as in the prevention and management of Alzheimer's disease. Various cognitive enhancer are
widely used traditionally as medicine to prevent Alzheimer's disease. Nutraceuticals are food or
part of a food including naturals (like plants, animals, minerals, or microbial sources) or
chemical groups (like vitamins, antioxidants, amino acids and fatty acids) that promote wellness
or health benefits including the prevention and/or treatment of a disease. One of the best benefits
of nutraceuticals is that they provide a better therapeutic hope with lesser side effects compared
to pharmaceutical agents or other conventional approach. Some of the herbal nutraceuticals like
Gingko Biloba, Huperzine Alpha are used in clinical practice to target the pathogenesis of
Alzheimer's disease.
KEYWORDS
Nutraceuticals, Alzheimer's disease, Herbal Drugs, Gingko Biloba, Huperzine
Alpha, Vitamins.
DOI
REFERENCES
1. Goodman Gilman A, Goodman LS, Rall TW,
Murad F Eds. Goodman & Gilman's The
Pharmacological Basis Of Therapeutics. New
York: Macmillan Publishing Company, 7th ed.
1985; pp 560-62
2. Dementia Fact Sheet, World Health
Organisation. 2016
3. Levine DA, Langa KM. Vascular cognitive
impairment: disease mechanisms and
therapeutic implications. Neurotherapeutics
2011; 8(3): 361–373
4. Skoog I. Status of risk factors for vascular
dementia. Neuroepidemiology 1998; 17(1):
2–9
5. Tiraboschi P, Hansen LA, Thal LJ, Corey-
Bloom J. The importance of neuritic plaques
and tangles to the development and evolution
of AD. Neurology 2004; 62(11): 1984-1989
6. Wright CI, Geula C, Mesulam MM:
Neurological cholinesterase in the normal
brain and in Alzheimer's disease: Relation to
plaques, tangles, and patterns of selective
vulnerability. Annals of Neurology 1993; 34:
373-384.
7. Francis PT, Palmer AM, Snape M, et al.,The
cholinergic hypothesis of Alzheimer's disease:
A review of progress. J Neurol ,neurosurg
Psychiatry 1999; 54: 137-147.
8. Brower V. Nutraceuticals: Poised for a
healthy slice of the healthcare market? Nature
Biotechnology 1998; 16: 728-731
9. Smith JV, Luo Y. Studies on molecular
mechanisms of Ginkgo biloba extract.
Applied Microbiology and Biotechnology
2004; 64(4): 465–472
10. http://www.herbal-supplement-resource.com
11. http://www.richters.com
12. Maurer K, Ihl R, Dierks T, Frolich L. Clinical
efficacy of Ginkgo biloba special extract EGb
761 in dementia of the Alzheimer type.
Journal of Psychiatric Research 1997; 31(6):
645–655
13. Mazza M, Capuano A, Bria P, Mazza S.
Ginkgo biloba and donepezil: a comparison
in the treatment of Alzheimer‟s dementia in a
randomized placebo-controlled double-blind
study. European Journal of Neurology 2006;
13(9): 981– 985
14. Wang R, Xi CT. Neuroprotective effects of
huperzine A: a natural cholinesterase
inhibitor for the treatment of Alzheimer‟s
disease. NeuroSignals 2005; 14(1-2): 71-82
15. http://www.holistictherapypractice.com
16. Zhang Z, Wang X, Chen Q, Shu L, Wang J,
Shan G. Clinical efficacy and safety of
huperzine Alpha in treatment of mild to
moderate Alzheimer disease, a placebo-
controlled, double-blind, randomized trial.
Zhonghua Yi Xue Za Zhi 2002; 82: 941-944
17. Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL,
Wang GQ, Su XQ, Zhong XS, Cheng RY,
Xu WA, et al. Huperzine-A in capsules and
tablets for treating patients with Alzheimer
disease. Zhongguo Yao Li Xue Bao 1999; 20:
486-490.
18. Perry EK, Pikering AT, Wang WW, et al.:
Medicinal plants and Alzheimer's disease:
Integrating ethnobotanical and contemporary
scientific evidence. Journal of Alternate and
Complementary Medicine 1998; 4: 419-428.
19. Kennedy DO, Scholey AB, Tildesley NTJ, et
al.: Modulation of mood and cognitive
performance following acute administration
of Melissa officinalis lemon balm. Pharmacol
ogy Biochemisty and Behavior 2002; 72: 953-
964.
20. Akhondzadeh S, Noroozian M, Mohammadi
M, et al.: Melissa officinalis extract in the
treatment ofpatients with mild to moderate
Alzheimer's disease: A double blind,
randomised, placebo controlled trial. Journal
of Neurology, Neurosurgery and Psychiatry
2003; 74: 863-866.
21. Wake G, Court J, Pikering A, et al.: CNS
acetylcholine receptor activity in European
medicinal plants traditionally used to improve
failing memory. Journal of
Ethnopharmacology 2000; 69: 105-114.
22. Akhondzadeh S, Noroozian M, Mohammadi
M, et al.: Salvia officinalis extract in the
treatment of patients with mild to moderate
Alzheimer's disease: A double blind,
randomized and placebo-controlled trial.
Journal of Clinical Pharmacy and
Therapeutics 2003; 28: 53-59.
23. Russo A, Borrelli F. Bacopa monniera, a
reputed nootropic plant: an overview. Phyto
medicine 2005; 12(4): 305-317
24. Bhattacharya SK, Bhattacharya A, Kumar A,
Ghosal S. Antioxidant activity of Bacopa
monniera in rat frontal cortex, striatum and
hippocampus. Phytotherapy Research 2000;
14(3): 174–179
25. Russo A, Izzo AA, Borrelli F, Renis M,
Vanella A. Free radicalbscavenging capacity
and protective effect of Bacopa monniera L.
on DNA damage. Phytotherapy Research
2003; 17(8): 870-875
26. Kamkaew N, Scholfield CN, Ingkaninan K,
N. Taepavarapruk N, Chootip K. Bacopa
monnieri increases cerebral blood flow in rat
independent of blood pressure. Phytotherapy
Research 2013; 27(1): 135-138
27. Kar Chowdhuri D, Parmar D, Kakkar P,
Shukla R, Seth PK, Srimal RC. Antistress
effects of bacosides of Bacopa monnieri
modulation of Hsp70 expression, superoxide
dismutase and cytochrome P450 activity in
rat brain. Phytotherapy Research 2002; 16(7):
639-645
28. Kishore K, Singh M. Effect of bacosides,
alcoholic extract of Bacopa monniera
Linn.(brahmi) on experimental amnesia in
mice. Indian Journal of Experimental Biology
2005; 43(7): 640-645
29. Goswami S, Saoji A, Kumar N, Thawani V,
Tiwari M, Thawani M. Effect of Bacopa
monnieri on Cognitive functions in
Alzheimer‟s disease patients. International
Journal of Collaborative Research in Internal
Medicine and Public Health 2011; 3: 285-293.
30. http://www.alz.org/research/science/alzhei
mers treatment horizon.asp
31. http://www.alz.org/research/clinical
trials/find clinical trials trialmatch.aspf